ICD-10 Code C81.20 | Mixed cellularity Hodgkin lymphoma, unsp site Symptoms, Diagnosis, Billing

Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma characterized by a mixture of cell types, including Reed-Sternberg cells. It typically presents with lymphadenopathy, fever, night sweats, and weight loss. Accurate coding with ICD-10 Code C81.20 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that patients receive appropriate care and resources.

What is ICD-10 Code C81.20 for Mixed cellularity Hodgkin lymphoma, unsp site?

ICD-10 Code C81.20 represents Mixed cellularity Hodgkin lymphoma at an unspecified site. This condition is a type of lymphatic cancer that involves a heterogeneous population of cells. The code should be used when documenting cases of this lymphoma subtype, particularly when the specific site of involvement is not identified, ensuring accurate billing and clinical documentation.

ICD-10 Code C81.20 – Clinical Definition and Explanation of Mixed cellularity Hodgkin lymphoma, unsp site

Mixed cellularity Hodgkin lymphoma is primarily caused by the proliferation of abnormal lymphocytes, particularly Reed-Sternberg cells. The disease can progress to involve multiple lymph nodes and may lead to systemic symptoms. Prompt medical attention is crucial for effective management and treatment.

Key Clinical Features:

• Presence of lymphadenopathy, often in cervical or axillary regions.
• Systemic symptoms such as fever, night sweats, and unexplained weight loss.
• Potential for splenomegaly and hepatomegaly.
• Diagnosis typically confirmed through biopsy and histological examination.

ICD-10 Code C81.20 for Mixed cellularity Hodgkin lymphoma, unsp site – SOAP Notes & Clinical Use

ICD-10 Code C81.20 is utilized in SOAP notes to document the patient's symptoms, assessment findings, and treatment plans. This code is relevant in both acute and chronic care settings, facilitating comprehensive patient management and accurate billing.

What Does ICD-10 Code C81.20 for Mixed cellularity Hodgkin lymphoma, unsp site Mean in SOAP Notes?

In SOAP notes, ICD-10 Code C81.20 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of Mixed cellularity Hodgkin lymphoma. This ensures continuity of care, supports billing processes, and meets EHR documentation standards.

Treatment Options for ICD-10 Code C81.20 – Mixed cellularity Hodgkin lymphoma, unsp site

Management of Mixed cellularity Hodgkin lymphoma often requires hospitalization for treatment initiation and monitoring.

Antibiotic Therapy:

• Not applicable as this is not an infectious condition.

Supportive Care:

• Symptom management including pain relief and antiemetics.
• Nutritional support to address weight loss.
• Psychosocial support for emotional well-being.

Infection Control:

• Standard precautions to prevent infections during treatment.
• Monitoring for febrile neutropenia in patients undergoing chemotherapy.

How to Document Symptoms of Mixed cellularity Hodgkin lymphoma, unsp site (ICD-10 C81.20) in SOAP Notes

Subjective:

• Patient reports persistent lymphadenopathy in the neck.
• Experiencing night sweats and unintentional weight loss of 10 pounds over the last month.
• Complains of fatigue and occasional fevers.

Objective:

• Physical examination reveals enlarged cervical lymph nodes.
• Temperature recorded at 100.5°F.
• Blood tests show elevated white blood cell count.

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Mixed cellularity Hodgkin lymphoma, unsp site (ICD-10 Code C81.20)

Assessment:

• Diagnosis: Mixed cellularity Hodgkin lymphoma, unspecified site, moderate severity.
• ICD-10 Code: C81.20.
• Contributing factors include age and gender predisposition.

Plan:

• Initiate chemotherapy regimen as per oncology guidelines.
• Educate patient on potential side effects and symptom management.
• Schedule follow-up appointments for monitoring treatment response.

Treatment & Plan Section for ICD-10 Code C81.20 – Mixed cellularity Hodgkin lymphoma, unsp site

• First-line treatment typically includes ABVD chemotherapy regimen.
• Non-pharmacologic strategies include nutritional counseling and psychosocial support.
• Monitoring through regular imaging and blood tests to assess treatment efficacy.
• Follow-up visits every 1-3 months during active treatment phase.

Using ICD-10 Code C81.20 for Mixed cellularity Hodgkin lymphoma, unsp site in Billing & SOAP Note Compliance

• Select appropriate ICD-10 code based on clinical documentation of the condition.
• Ensure Subjective (S) and Objective (O) findings are clearly documented in SOAP notes.
• Align treatment plans with clinical guidelines to support justified billing.
• Include only relevant CPT codes that correspond with the services provided.

Related ICD-10 Codes Often Used with Mixed cellularity Hodgkin lymphoma, unsp site

• C81.30 – Lymphocyte-rich Hodgkin lymphoma, unsp site
• C81.90 – Hodgkin lymphoma, unsp type, unsp site

ICD-10 Code C81.20 in Medical Billing and Insurance for Mixed cellularity Hodgkin lymphoma, unsp site

ICD-10 Code C81.20 is crucial for accurate billing in hospital, ER, or oncology settings.

Billing Notes:

• Document all relevant clinical findings and treatment plans to support the ICD-10 claim.
• Use this code in conjunction with specific treatment codes for comprehensive billing.
• Ensure that all documentation aligns with payer requirements for reimbursement.

Common CPT Pairings: